HBV-Encoded miR-2 Functions as an Oncogene by Downregulating TRIM35 But Upregulating RAN in Liver Cancer Cells

Yao, Lili; Sui, Zhenhua; Liu, Yan-Kun; Xie, Hong; Gao, Huijie; Fan, Hongxia; Zhang, Yi; Liu, Min; Li, Shengping; Tang, Hua

doi:10.2139/ssrn.3365052

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV-miR-3 was shown to restrict HBV replication, by targeting the region of HBV 3.5-kb mRNA encoding HBV core antigen (HBc) (79). Another HBV-encoded miRNA, HBV-miR-2, can promote the oncogenic activity of liver cancer cells (80). HBV-encoded miRNAs likely contribute to HBV-specific HCC development.…”

Section: Mechanism Of Mirna Dysregulation In Hccmentioning

confidence: 99%

Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets

Winkler

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are non-coding small RNAs that can function as gene regulators and are involved in tumorigenesis. We review the commonly dysregulated miRNAs in liver tumor tissues and plasma/serum of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. The frequently reported up-regulated miRNAs in liver tumor tissues include miR-18a, miR-21, miR-221, miR-222, and miR-224, whereas down-regulated miRNAs include miR-26a, miR-101, miR-122, miR-125b, miR-145, miR-199a, miR-199b, miR-200a, and miR-223. For a subset of these miRNAs (up-regulated miR-222 and miR-224, down-regulated miR-26a and miR-125b), the pattern of dysregulated circulating miRNAs in plasma/serum is mirrored in tumor tissue based on multiple independent studies. Dysregulated miRNAs target oncogenes or tumor suppressor genes involved in hepatocarcinogenesis. Normalization of dysregulated miRNAs by up-or down-regulation has been shown to inhibit HCC cell proliferation or sensitize liver cancer cells to chemotherapeutic treatment. miRNAs hold as yet unrealized potential as biomarkers for early detection of HCC and as precision therapeutic targets, but further studies in diverse populations and across all stages of HCC are needed.

show abstract

Section: Mechanism Of Mirna Dysregulation In Hccmentioning

confidence: 99%

Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets

Winkler

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Multiple miRNA directly target HBV transcripts and examples of these include miR-184/-185/-196a/-199a-3p/-210/-217 that are all significantly upregulated [28]. Recently it was also discovered that the HBV virion generates its own HBV-miR-2/-3 [37]. HBV-miR-3 suppresses the hepatitis B core protein (HBc) mRNA to self-regulate HBV expression downwards [27], possibly in order to promote its survival by way of avoiding the host immune system [28,38] (see Scheme 1, pathway 6).…”

Section: Hbv-induced Inflammation Pathwaysmentioning

confidence: 99%

The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis

Sartorius

Makarova

Sartorius

et al. 2019

Cells

View full text Add to dashboard Cite

The incidence and mortality of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HBV-HCC) is an intractable public health problem in developing countries that is compounded by limited early detection and therapeutic options. Despite the early promise of utilizing the regulatory role of miRNA in liver cancer, this field remains largely in the work-in-progress phase. This exploratory review paper adopts a broad focus in order to collate evidence of the regulatory role of miRNA in each stage of the HBV-HCC continuum. This includes the regulatory role of miRNA in early HBV infection, chronic inflammation, fibrosis/cirrhosis, and the onset of HCC. The paper specifically investigates HBV dysregulated miRNA that influence the expression of the host/HBV genome in HBV-HCC pathogenesis and fully acknowledges that this does not cover the full spectrum of dysregulated miRNA. The sheer number of dysregulated miRNA in each phase support a hypothesis that future therapeutic interventions will need to consider incorporating multiple miRNA panels.An estimated 841,080 new liver cancers (LCs) were diagnosed worldwide in 2018, with hepatocellular carcinoma (HCC), the most common histological subtype, accounting for 75% to 90% of LCs [1]. A 12.4% increase of LC was recorded between 2008 (696,000) to 2012 (782,000) [2] and [3] 7.6% between 2012 and 2018 (841,080) [1]. HCC is listed globally as a leading cancer in men and women [4], with a recent report indicating that 83% of new cases diagnosed occurred in less well

show abstract

“…Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the fifth most common incidence rate (Yao et al 2019), and it has a poor prognosis (Liang et al 2018). About 800,000 of new cases of HCC in each year were examined worldwide, People's Republic of China count more than 50% of these cases (Gingold et al 2018).…”

Section: Introductionmentioning

confidence: 99%

Role of the autophagy-related marker LC3 expression in hepatocellular carcinoma: a meta-analysis

Meng

Lou

Yang

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Microtubule-associated protein 1 light chain 3 (LC3), an autophagic gene, has been reported as a vital marker for many diseases and cancers. However, the role of LC3 in hepatocellular carcinoma (HCC) was not still investigated. Therefore, we conducted a meta-analysis to examine the association of LC3 with its clinicopathological and prognostic in HCC. Methods We consulted the PubMed, Cochrane Library, Web of Science, EMBASE, China National Knowledge Infrastructure and Wan Fang databases for published studies on LC3 in HCC. Newcastle-Ottawa scale was used to screen the quality of the literature. The statistical analysis was calculated by STATA 14.2. Results Of the 1329 titles identified, 10 articles involving 949 patients in HCC were included in this meta-analysis. The results of our study show that increased LC3 expression is related to size of tumor, but not to gender, age, number of tumor, liver cirrhosis, HBsAg, TNM stage, alpha fetoprotein, vascular invasion and histological grade. Positive LC3 expression was associated with overall survival by pooled hazard ratio. Conclusions This meta-analysis indicated that positive LC3 expression was related to size of tumor, and could predict prognosis in human hepatocellular carcinoma.

show abstract

HBV-Encoded miR-2 Functions as an Oncogene by Downregulating TRIM35 But Upregulating RAN in Liver Cancer Cells

Cited by 8 publications

References 0 publications

Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets

Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets

The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis

Role of the autophagy-related marker LC3 expression in hepatocellular carcinoma: a meta-analysis

Contact Info

Product

Resources

About